Evaluate the Use of Glibenclamide on Acute aSAH

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

110 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-19

Study Completion Date

2022-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized, open-labeled, blank-controlled and prospective trial meant to evaluate the use of glibenclamide on acute aneurysmatic subarachnoid hemorrhage. Patients will allocated randomly in two groups, one for 3.75 mg daily intake of glibenclamide for 7 days and another as a blank contrast. General clinical data and late cognitive status will be accessed in both groups.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Glibenclamide Combined With Rt-PA in Acute Cerebral Embolism

NCT03284463

Acute Stroke

COMPLETED PHASE2/PHASE3

Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid Hemorrhage

NCT01787123

Subarachnoid Hemorrhage Intracranial Aneurysm Delayed Cerebral Ischemia +1 more

COMPLETED PHASE2/PHASE3

Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage

NCT03741530

Intracerebral Hemorrhage

COMPLETED NA

Evaluation of CN-105 in Subject With Acute Supratentorial Intracerebral Hemorrhage

NCT03711903

Intracerebral Hemorrhage

COMPLETED PHASE2

Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage

NCT02560532

Aneurysmal Subarachnoid Hemorrhage

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is a open-labeled, blank-controlled, prospective and randomized clinical trial, conducted at Tiantan Hospital and Tongren Hospital, affiliated with the Capital Medical University. Patients will be recruited from intensive care units. Appropriate ethics and regulatory approvals will be sought for all subjects, according to the International Conference on Harmonization guidelines for good clinical practice (ICH GCP). Investigators will obtain informed written consent from all patients or their legal representative. Recruitment will take place between 2021 and 2022.

Patients will be randomly assigned (1:1) to receive either glibenclamide 3.75mg or blank contrast. A computer-generated randomization code will be used to randomize patients. Patients will start treatment as soon as possible within 48 h of the stroke, with a daily dose till the 7 days after the recruitment. Trial medication consisted of one and a half pieces of tablet a day, given orally or via a nasogastric tube. Aneurysm treatment, either by microsurgery or embolization, will be performed as soon as possible, according with the standard of care for the recruiting center. Nimodipine 60mg, every six hours, will be started on admission and continued till two weeks later, in all patients as standard of care.

Patient's demographics, medical history and relevant investigation results will be collected. The severity of the hemorrhage will be clinically assessed by World Federation of Neurosurgical Societies grading scale and radiologically using the modified Fischer scale. At 90 days of follow up patients will be interviewed with modified Rankin scale (mRS) questionnaire (a scale that measures degree of incapacity/ dependence and mortality after neurological events) by a physician with no knowledge of treatment allocation. The main hypothesis is that, once compared with standard of care, glibenclamide 3.75mg will provide better clinical outcome and additionally will decrease mortality and improve quality of life and cognitive performance after 90 days.

Sample size: Previous studies have shown that the NSE mean for the third day after subarachnoid hemorrhage is 21 ng/ml, the standard deviation is about 3 ng/ml, and the third day NSE in patients with a good prognosis group is about 19 ng/ml, and the standard deviation is about 3 ng/ml; according to the two-sided test, significance of 5%, two groups of equal number of people, 90% of the degree of certainty, the calculation of the sample size of 98 cases, assuming 10% of the loss of visits, the total sample size is expected to be 110 cases.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Subarachnoid Hemorrhage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Patients in the case group were treated with glibenclamide within 10 hours after onset, orally or through nasogastric tube, 1.25 mg each time, once every 8 hours, for 7 consecutive days. The control group was blank control.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Open label, result blind method

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental group

Glibenclamide was given orally or through nasogastric tube, 1.25 mg every 8 hours for 7 days

Group Type EXPERIMENTAL

glibenclamide

Intervention Type DRUG

Glibenclamide was given orally or by nasal feeding

Control group

No glibenclamide treatment

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

glibenclamide

Glibenclamide was given orally or by nasal feeding

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Glebenzene

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subarachnoid hemorrhage was diagnosed by digital subtraction angiography, computed tomographic angiogram or magnetic resonance angiography;
2. Within 48 hours;
3. Age \> 18 years old;
4. The expected length of stay is more than 7 days;
5. Sign informed consent.

Exclusion Criteria

1. There was a history of taking sulfonylureas within 30 days before brain injury;
2. Combined with neurological or mental diseases, including stroke, epilepsy and dementia;
3. Hunt \& Hess grade V patients;
4. Severe brain injury (central hernia or hook hernia within 48 hours after admission or after resuscitation) that cannot be solved at present;
5. History of alcohol or illicit drug dependence;
6. Allergic to sulfonamides or glibenclamide tablets;
7. The international normalized ratio was more than 1.4;
8. Renal insufficiency, history of dialysis treatment or serum creatinine more than 2.5 mg / dl;
9. Liver cirrhosis or severe liver dysfunction (ALT \> 2.5 times the upper normal limit or total bilirubin \> 1.5 times the upper normal limit);
10. He is taking bosentan tablets to treat pulmonary hypertension;
11. There was a history of glucose-6-phosphate dehydrogenase deficiency (faba bean disease);
12. The life expectancy is less than one year;
13. The gastrointestinal tract should not be used;
14. Pregnancy or lactation;
15. History of participating in other drug trials within 30 days;

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No